Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years
Summary by MyChesCo
2 Articles
2 Articles
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has expanded its Retina Scientific Advisory Board (SAB) and executive leadership team as the company accelerates toward filing three Biologics License Applications (BLAs) within the next three years. The updates are part of a broader push to enhance clinical execution and position the firm for commercial readiness. Chairman and CEO Dr. Shankar Musunuri said the moves reflect the company’s commitment to b…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium